Evidence map›Paper›PMID 27512673›Full record

ReviewOncolytic virotherapy2015

Oncolytic virotherapy for head and neck cancer: current research and future developments.

Akshiv Malhotra, Arun Sendilnathan, Matthew O Old, Trisha M Wise-Draper

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncolytic virotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Infection: a Cause of and Cure for Cancer.Current pharmacology reports · 2017
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Akshiv MalhotraDivision of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Arun SendilnathanDivision of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Matthew O OldDepartment of Otolaryngology-Head and Neck Surgery, Ohio State University, Columbus, OH, USA.
Trisha M Wise-DraperDivision of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
University of Cincinnati · USThe Ohio State University · US

Funding

LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI MEINZEN-DERR, JAREEN, STRAWN, JEFFREY ROBERT · 2015 to 2024
$37.5M
NCATS NIH HHS UL1 TR001425
6 · The paper itself

Abstract

Head and neck cancer (HNC) is the sixth most common malignancy worldwide. Despite recent advancements in surgical, chemotherapy, and radiation treatments, HNC remains a highly morbid and fatal disease. Unlike many other cancers, local control rather than systemic control is important for HNC survival. Therefore, novel local therapy in addition to systemic therapy is urgently needed. Oncolytic virotherapy holds promise in this regard as viruses can be injected intratumorally as well as intravenously with excellent safety profiles. This review will discuss the recent advancements in oncolytic virotherapy, highlighting some of the most promising candidates and modifications to date.

Indexed as

head and neck canceroncolytic virusesvirotherapy

Identifiers

PMID27512673
PMCPMC4918384
OpenAlexW1846079507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.